1. Phentolamine is a competitive, reversible, nonselective alpha adrenergic antagonist. Which of the following correctly identifies all receptor targets of phentolamine, explains the consequence of presynaptic alpha-2 receptor blockade, and identifies the clinical manifestation that results from this presynaptic effect?

• A) Phentolamine blocks only postsynaptic alpha-1 receptors on vascular smooth muscle and does not block presynaptic alpha-2 autoreceptors; this postsynaptic selectivity means that norepinephrine release from sympathetic terminals is regulated normally; reflex tachycardia from phentolamine is entirely baroreceptor-mediated rather than from increased NE release; this distinguishes phentolamine from phenoxybenzamine, which blocks both compartments.
• B) Phentolamine blocks both postsynaptic alpha-1 receptors on vascular smooth muscle (producing vasodilation and blood pressure reduction) and presynaptic alpha-2 autoreceptors on sympathetic nerve terminals; the presynaptic alpha-2 receptors normally serve as negative feedback regulators that reduce NE release when synaptic NE rises; phentolamine blocks this negative feedback, disinhibiting NE release from sympathetic terminals; the increased NE release then activates cardiac beta-1 receptors (not blocked by phentolamine) causing tachycardia and increased contractility -- a reflex tachycardia that is both baroreceptor-mediated and pharmacologically amplified by the loss of presynaptic alpha-2 autoreceptor inhibition; this reflex tachycardia is clinically significant in patients with ischemic heart disease and can be attenuated by concurrent beta-blockade, but only after adequate alpha blockade has been established.
• C) Phentolamine blocks postsynaptic alpha-1 and postsynaptic alpha-2 receptors on vascular smooth muscle but presynaptic alpha-2 autoreceptors are structurally resistant to phentolamine binding due to their intracellular loop configuration; the tachycardia from phentolamine is solely baroreceptor-mediated from the fall in blood pressure and does not involve any change in presynaptic NE release.
• D) Phentolamine blocks presynaptic alpha-2 autoreceptors selectively without blocking postsynaptic alpha-1 receptors; the selective presynaptic blockade disinhibits NE release, and the resulting NE surge activates both alpha-1 and beta-1 receptors; phentolamine is therefore classified as an indirect sympathomimetic rather than an alpha antagonist because its net effect is increased adrenergic stimulation from increased NE release.

2. Phenoxybenzamine is a non-competitive, irreversible alpha adrenergic antagonist. Which of the following correctly identifies the molecular mechanism of its irreversibility and explains why this mechanism is pharmacologically distinct from that of phentolamine?

• A) Phenoxybenzamine is irreversible because it has an extremely high binding affinity for alpha-1 receptors in the femtomolar range, making dissociation kinetically negligible under physiological conditions; this ultra-high affinity competitive binding is the basis for calling it non-competitive, because no physiologically achievable NE concentration can displace it; phentolamine has lower affinity and can be displaced by high NE concentrations, which is why phentolamine is classified as competitive and reversible.
• B) Phenoxybenzamine undergoes spontaneous oxidation in tissue after receptor binding, converting to a reactive quinone intermediate that irreversibly cross-links adjacent receptor proteins; this oxidative cross-linking is reversed by N-acetylcysteine, which is used clinically to reverse phenoxybenzamine toxicity; phentolamine does not undergo oxidative conversion and cannot cross-link receptors.
• C) Phenoxybenzamine irreversibility results from its high lipophilicity causing it to partition into the cell membrane lipid bilayer adjacent to the receptor; from this membrane depot it continuously rebinds the receptor as fast as it dissociates, producing apparent irreversibility; the drug is not covalently bound to the receptor protein; recovery occurs as phenoxybenzamine is gradually metabolized from the membrane depot over days.
• D) Phenoxybenzamine is a haloalkylamine that undergoes intramolecular cyclization to form a highly reactive ethylenimine (aziridinium) intermediate that covalently alkylates nucleophilic residues in the ligand-binding domain of both alpha-1 and alpha-2 adrenergic receptors; this covalent bond is irreversible under physiological conditions and cannot be displaced by any concentration of agonist or competitive antagonist regardless of how high; recovery from phenoxybenzamine blockade requires synthesis of new adrenergic receptor protein from the ADRA1 and ADRA2 (alpha-1 and alpha-2 adrenergic receptor genes), a process taking days to weeks; this irreversible covalent mechanism is pharmacologically distinct from phentolamine, which binds non-covalently with reversible competitive kinetics and can be displaced if agonist concentrations rise sufficiently high.

3. In preoperative preparation of a pheochromocytoma patient for adrenalectomy, alpha blockade must be established before beta blockade is initiated. Which of the following correctly identifies the pharmacological consequence of reversing this sequence?

• A) If a beta-blocker is administered before alpha blockade in a patient with pheochromocytoma, the beta-2-mediated vasodilation that partially offsets the alpha-1-mediated vasoconstriction from tumor-secreted catecholamines is blocked; the result is unopposed alpha-1 vasoconstriction from continued tumor catecholamine secretion -- peripheral vascular resistance rises dramatically, blood pressure worsens, and the patient may develop a hypertensive crisis; additionally, beta-1 blockade reduces cardiac output while SVR is maximal, potentially precipitating cardiac decompensation; beta blockade without prior alpha blockade in pheochromocytoma is therefore a potentially life-threatening prescribing error.
• B) Administering a beta-blocker before alpha blockade in pheochromocytoma is pharmacologically safe and the sequence does not matter clinically; the concern about unopposed alpha stimulation is theoretical and not documented in controlled trials; beta-blockers reduce the cardiovascular stress of catecholamine excess by slowing heart rate and reducing contractility, which is beneficial regardless of whether alpha blockade is established first; the alpha-before-beta sequence is a clinical convention rather than a pharmacological requirement.
• C) Administering a beta-blocker before alpha blockade in pheochromocytoma causes serotonin syndrome because beta-1 receptor blockade inhibits MAO-A activity as an off-target effect, preventing degradation of tumor-derived serotonin; the accumulated serotonin combined with the adrenergic excess produces a combined serotonin syndrome and catecholamine crisis.
• D) Administering a beta-blocker before alpha blockade causes dangerous bradycardia because the pheochromocytoma patient is in a high-catecholamine state with maximal beta-1 stimulation; abrupt beta-1 blockade removes this catecholamine-driven chronotropy so rapidly that a rebound bradycardia occurs analogous to the rebound hypertension seen after clonidine withdrawal; bradycardia is the primary danger rather than any vascular effect.

4. Selective alpha-1 blockers such as prazosin, terazosin, and doxazosin produce less reflex tachycardia than nonselective alpha blockers such as phentolamine. Which of the following correctly identifies the pharmacological mechanism for this difference?

• A) Selective alpha-1 blockers produce less reflex tachycardia because they also weakly block cardiac beta-1 receptors as an off-target effect; this weak beta-1 antagonism directly attenuates the cardiac response to increased sympathetic drive from the baroreceptor reflex; phentolamine lacks this off-target beta-1 blocking property and therefore allows full cardiac beta-1 activation in response to the vasodilation-induced baroreflex.
• B) Selective alpha-1 blockers produce less reflex tachycardia because they cause less blood pressure reduction than nonselective agents; the smaller antihypertensive effect triggers a smaller baroreflex response; phentolamine produces more blood pressure reduction because it blocks both alpha-1 and alpha-2 receptors on vascular smooth muscle, adding a vascular alpha-2 blockade component to the vasodilation.
• C) Selective alpha-1 blockers spare the presynaptic alpha-2 autoreceptors on sympathetic nerve terminals; the preserved alpha-2 autoreceptors continue to provide negative feedback on norepinephrine release -- when sympathetic activity increases in response to the vasodilation-induced baroreflex, released NE activates the presynaptic alpha-2 autoreceptors and reduces further NE release, attenuating the net sympathetic outflow to the heart; nonselective blockers such as phentolamine block these presynaptic alpha-2 autoreceptors simultaneously with the postsynaptic alpha-1 receptors, removing this negative feedback brake and allowing NE release to increase unchecked, producing more pronounced tachycardia.
• D) Selective alpha-1 blockers also block alpha-2 receptors in the central nervous system at therapeutic doses, producing central sympatholysis that reduces baroreflex-mediated sympathetic outflow to the heart analogous to clonidine; phentolamine does not cross the blood-brain barrier and cannot produce central sympatholysis, accounting for its more pronounced peripheral tachycardia.

5. Prazosin is associated with a significant first-dose phenomenon -- an acute episode of orthostatic hypotension and sometimes syncope occurring within 30-90 minutes of the initial dose. Which of the following correctly identifies the mechanism of this first-dose effect and the specific measure that most effectively reduces its risk?

• A) The first-dose phenomenon of prazosin is caused by a pharmacokinetic spike -- prazosin undergoes rapid saturable first-pass hepatic metabolism; at the first dose, hepatic enzymes are not yet induced, so bioavailability is much higher than at subsequent doses; the unexpectedly high plasma prazosin concentration produces dramatically greater alpha-1 blockade than anticipated; subsequent doses encounter fully induced hepatic enzymes and produce more predictable plasma levels; the prevention strategy is administering a test dose of 0.1 mg to assess individual first-pass metabolism.
• B) The first-dose phenomenon results from an acute allergic reaction to prazosin's quinazoline ring structure in previously sensitized patients; it is immunological rather than pharmacodynamic; it can be predicted by a prazosin skin-prick test before initiating therapy; antihistamine pretreatment significantly reduces the incidence; subsequent doses do not cause the same reaction because IgE-mediated desensitization occurs after the first exposure.
• C) The first-dose phenomenon results from alpha-1 receptor upregulation in hypertensive patients -- prolonged sympathetic overdrive from hypertension increases alpha-1 receptor density on vascular smooth muscle; the first dose of prazosin blocks these upregulated receptors, producing vasodilation far in excess of what would occur in normotensive patients; subsequent doses are less dramatic because prolonged alpha-1 blockade causes receptor downregulation back toward normal density.
• D) The first-dose phenomenon results from prazosin's simultaneous arteriolar and venous dilation producing a sudden reduction in both peripheral vascular resistance and venous return before any compensatory mechanisms have adapted; the fall in preload reduces cardiac output; the fall in SVR reduces MAP; the combined effect produces orthostatic hypotension that is particularly severe on standing due to gravitational pooling of blood in venous capacitance vessels; the heart rate response is attenuated because venous dilation reduces venous return, blunting the baroreflex-mediated tachycardia; the most effective prevention strategy is administering the first dose at bedtime in the recumbent position at the lowest available dose (0.5-1 mg) to limit the magnitude of initial vasodilation.
• E) The first-dose phenomenon results from prazosin's simultaneous arteriolar and venous alpha-1 blockade producing a sudden, unadapted reduction in both peripheral vascular resistance and venous return; no compensatory cardiovascular mechanisms have yet adapted to the vasodilation; on standing, gravitational pooling compounds the venous dilation and the impaired venoconstriction reflex cannot adequately compensate; the single most effective prevention strategy is administering the initial dose at bedtime with the patient recumbent at the lowest available dose (0.5-1 mg), which limits the blood pressure fall to a period when the patient is horizontal, minimizing the gravitational contribution to orthostasis and allowing overnight cardiovascular adaptation before the patient assumes upright posture; subsequent doses produce progressively less orthostatic hypotension as compensatory adaptations develop; the patient must be counseled explicitly not to rise suddenly after taking the first dose.

6. The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) evaluated doxazosin as antihypertensive monotherapy. Which of the following correctly identifies what the trial found and its primary clinical consequence for the prescribing of alpha-1 blockers in hypertension?

• A) The ALLHAT trial demonstrated that doxazosin was superior to chlorthalidone for reducing the primary endpoint of fatal coronary heart disease and non-fatal myocardial infarction, establishing doxazosin as a preferred first-line antihypertensive agent in high-cardiovascular-risk patients; its superior efficacy was attributed to favorable metabolic effects including lipid lowering and insulin sensitization that chlorthalidone lacks.
• B) The ALLHAT trial demonstrated that doxazosin was associated with a significantly higher rate of combined cardiovascular disease events -- driven primarily by a nearly doubled rate of heart failure compared to chlorthalidone -- despite achieving similar blood pressure reduction, leading to early termination of the doxazosin arm; this finding substantially reduced enthusiasm for alpha-1 blockers as first-line antihypertensive monotherapy, and current guidelines generally recommend their use as add-on therapy (particularly in men with concurrent BPH) rather than as initial treatment for hypertension.
• C) The ALLHAT trial found doxazosin equivalent to chlorthalidone for all cardiovascular endpoints including heart failure, stroke, and myocardial infarction, but found that doxazosin produced more sexual dysfunction than chlorthalidone; this led to the recommendation that doxazosin be used as second-line therapy in patients concerned about sexual adverse effects of thiazide diuretics, but not due to any cardiovascular outcome inferiority.
• D) The ALLHAT trial was a pharmacokinetic study finding that doxazosin's 24-hour half-life provided superior blood pressure control compared to chlorthalidone's shorter duration; cardiovascular outcomes were not assessed in ALLHAT because it was not powered for outcome comparison between drug classes; the trial's clinical consequence was the development of doxazosin XL to further optimize pharmacokinetics.

7. Tamsulosin is classified as a uroselective alpha-1 blocker for BPH. Which of the following correctly identifies the pharmacological basis of its uroSelectivity and explains why it produces less orthostatic hypotension than prazosin at therapeutically equivalent BPH doses?

• A) Tamsulosin's uroSelectivity results from its preferential binding to the alpha-1C subtype expressed exclusively in prostatic tissue with zero affinity for the alpha-1A and alpha-1B receptor subtypes found in the vasculature; the complete absence of vascular receptor binding accounts for complete absence of orthostatic hypotension at any dose; tamsulosin can therefore be initiated at a full therapeutic dose without any precautions about postural hypotension.
• B) Tamsulosin's uroSelectivity is pharmacokinetic rather than receptor-based: tamsulosin is selectively transported by the prostate-specific membrane antigen (PSMA) carrier from the bloodstream into prostatic epithelium, concentrating the drug 50-fold in the prostate relative to plasma; vascular smooth muscle lacks PSMA expression and has minimal exposure to tamsulosin; this prostatic-selective distribution rather than receptor subtype selectivity accounts for the reduced cardiovascular effects.
• C) Tamsulosin's uroSelectivity results from alpha-1A and alpha-1D subtypes predominating in prostatic stromal smooth muscle, the bladder neck, and proximal urethra; systemic vascular smooth muscle tone is more dependent on alpha-1B receptors; tamsulosin has preferential affinity for alpha-1A and alpha-1D relative to alpha-1B (approximately 10:1 selectivity), producing prostatic smooth muscle relaxation while having substantially less effect on systemic vascular resistance; the residual alpha-1B activity means orthostatic hypotension still occurs but less commonly and less severely than with non-subtype-selective agents such as prazosin.
• D) Tamsulosin has preferential affinity for alpha-1A and alpha-1D receptor subtypes, which predominate in prostatic stromal smooth muscle, the bladder neck, and the proximal urethra -- the smooth muscle targets whose relaxation relieves lower urinary tract symptoms in BPH; systemic vascular smooth muscle tone maintaining blood pressure is more dependent on the alpha-1B subtype, which tamsulosin blocks with substantially less potency; this receptor subtype selectivity (alpha-1A/D >> alpha-1B) allows tamsulosin to relax the lower urinary tract smooth muscle at doses that have substantially less effect on systemic vascular resistance, producing meaningful BPH symptom relief with a markedly lower incidence of orthostatic hypotension compared to prazosin, terazosin, or doxazosin, which do not discriminate between alpha-1 subtypes; tamsulosin can therefore be initiated at a full therapeutic dose (0.4 mg daily) without the bedtime first-dose precautions required by non-subtype-selective agents.

8. A 72-year-old man who took tamsulosin for 4 years for BPH discontinued it 8 weeks ago and is now scheduled for phacoemulsification cataract surgery. His ophthalmologist asks whether he is at risk for intraoperative floppy iris syndrome. Which of the following correctly characterizes the risk and the required surgical approach?

• A) This patient remains at elevated risk for intraoperative floppy iris syndrome (IFIS) despite 8 weeks of tamsulosin discontinuation; IFIS is not eliminated by preoperative drug cessation because the iris dilator smooth muscle changes associated with alpha-1A receptor blockade in the iris persist long after the drug is discontinued -- possibly involving lasting functional changes in iris dilator smooth muscle contractility and possibly structural iris changes; the ophthalmologist must be informed of the prior tamsulosin use regardless of when it was discontinued; surgical preparation should include use of iris expansion devices (iris hooks or Malyugin ring), intracameral phenylephrine (to pharmacologically stimulate iris dilator despite the persistent alpha-1 receptor effects), and modified phacoemulsification technique to reduce the risk of iris billowing, progressive intraoperative miosis, and iris prolapse that characterize the IFIS triad.
• B) This patient has no elevated risk for IFIS because 8 weeks of tamsulosin discontinuation is sufficient for full pharmacological reversal; tamsulosin's half-life is approximately 9-13 hours, meaning plasma levels are undetectable within 3-5 days of the last dose; once the drug is cleared from the iris tissue (complete within 2 weeks of discontinuation), iris dilator smooth muscle function fully recovers; 8 weeks exceeds this recovery period by a wide margin and the iris will behave normally during surgery.
• C) The risk of IFIS has been reduced but not eliminated by tamsulosin discontinuation; the residual risk after 8 weeks is approximately 20% of the risk during active tamsulosin therapy; the ophthalmologist should use a slightly wider starting incision to accommodate the mildly reduced iris rigidity but does not need the full IFIS surgical modification protocol; intracameral phenylephrine is not indicated for this patient's level of residual risk.
• D) This patient's IFIS risk depends entirely on whether he has now switched to a different alpha-1 blocker for BPH management; if he is taking no alpha-1 blocker, the prior tamsulosin exposure carries no residual IFIS risk after 8 weeks; the ophthalmologist needs only to confirm current medication status and does not need to account for historical tamsulosin use.

9. Silodosin has the highest alpha-1A receptor selectivity of any currently available alpha-1 blocker. Which of the following correctly identifies the clinical consequence of this extreme alpha-1A selectivity and the specific adverse effect most pronounced with silodosin compared to other uroselective agents?

• A) Silodosin's extreme alpha-1A selectivity produces a completely cardiovascular-neutral BPH therapy -- at approved doses, silodosin produces absolutely no change in systolic blood pressure on standing and zero incidence of orthostatic hypotension in clinical trials; this complete cardiovascular neutrality is the principal clinical advantage and is the reason silodosin is preferred over tamsulosin in elderly patients with orthostatic hypotension risk; the most pronounced adverse effect is dry mouth from alpha-1A blockade in salivary glands.
• B) Silodosin's extreme alpha-1A selectivity means it has the highest cardiovascular risk of all uroselective agents because alpha-1A receptors are the dominant subtype in coronary arteries; silodosin's preferential alpha-1A blockade in the coronary vasculature produces coronary vasodilation that paradoxically triggers compensatory coronary vasospasm through an alpha-2-mediated reflex mechanism, increasing the risk of unstable angina; the most pronounced adverse effect is chest pain requiring electrocardiographic monitoring.
• C) Silodosin's extreme alpha-1A selectivity -- with an alpha-1A to alpha-1B selectivity ratio of approximately 162:1 -- produces highly effective BPH symptom relief with minimal orthostatic hypotension (because alpha-1B vascular smooth muscle is largely spared); however, the very high alpha-1A affinity also strongly blocks alpha-1A receptors in the vas deferens, seminal vesicles, and bladder neck that coordinate antegrade ejaculation; the pharmacological consequence is the highest incidence of retrograde ejaculation of any alpha-1 blocker -- approximately 22-28% of patients in clinical trials experience retrograde ejaculation or anejaculation with silodosin -- making it a material prescribing consideration for sexually active men of reproductive age or those for whom ejaculatory function is important.
• D) Silodosin's extreme alpha-1A selectivity produces such complete prostatic smooth muscle relaxation that urinary retention from complete bladder outlet relaxation causing detrusor-urethral dyssynergia is the most common adverse effect requiring drug discontinuation; the internal urethral sphincter cannot provide adequate resistance for bladder filling, resulting in continuous dribbling; this is a class effect of all uroselective alpha-1 blockers but is most severe with silodosin.

10. Prazosin has an established off-label indication for PTSD (post-traumatic stress disorder)-related nightmares. Which of the following correctly identifies the central pharmacological mechanism by which prazosin reduces PTSD nightmare activity?

• A) Prazosin reduces PTSD nightmares through a peripheral mechanism -- by lowering nighttime blood pressure, prazosin reduces the cardiovascular arousal that triggers awakening from nightmares; the nightmares themselves are not pharmacologically altered but the patient is less likely to fully awaken because the cardiovascular stress response is attenuated; the central noradrenergic circuitry is not the pharmacological target.
• B) Prazosin reduces PTSD nightmares by blocking alpha-1 receptors in the reticular activating system of the brainstem, suppressing REM sleep generation; because PTSD nightmares occur primarily during REM sleep, reducing total REM sleep time with prazosin decreases the number of opportunities for nightmare occurrence; the tradeoff is reduced dream sleep and potentially impaired memory consolidation.
• C) Prazosin reduces PTSD nightmares through a serotonergic mechanism -- prazosin's alpha-1 blockade in the dorsal raphe nucleus reduces noradrenergic suppression of serotonin release; increased serotonergic tone from the raphe nuclei then activates 5-HT2A receptors in the amygdala reducing fear memory consolidation; prazosin is therefore equivalent to SSRIs for PTSD treatment through this shared serotonergic mechanism.
• D) Prazosin reduces PTSD nightmares by blocking alpha-1 receptors on peripheral sympathetic nerve terminals innervating the adrenal medulla, reducing epinephrine secretion during sleep; reduced circulating epinephrine prevents the cardiovascular and physiological arousal that activates amygdala fear circuits and precipitates nightmare content; this peripheral adrenomedullary mechanism is the primary therapeutic target.
• E) Prazosin reduces PTSD nightmares through central alpha-1 adrenergic receptor blockade in noradrenergic projection circuits -- particularly the locus coeruleus projections to the amygdala, prefrontal cortex, and hippocampus; in PTSD, chronically elevated central noradrenergic tone from hyperactivation of the locus coeruleus stress response drives hyperarousal, fear memory reconsolidation, and the intrusive nightmare activity that occurs during REM sleep; prazosin's alpha-1 blockade in these central noradrenergic target regions reduces norepinephrine-mediated amygdala hyperactivation and prefrontal cortex dysregulation, attenuating the hyperarousal-driven nightmare generation; this central mechanism is supported by the dose-response relationship between prazosin and nightmare reduction and by the observation that the degree of nightmare suppression correlates with central rather than peripheral blood pressure reduction.

11. A 65-year-old man with BPH on tamsulosin 0.4 mg daily is prescribed sildenafil 50 mg as needed for erectile dysfunction. Which of the following correctly identifies the pharmacodynamic mechanism of the drug interaction and the clinical consequence?

• A) Tamsulosin and sildenafil do not have a clinically significant pharmacodynamic interaction because they act on entirely different receptor systems in different tissues -- tamsulosin acts on alpha-1A receptors in the prostate (a urological target) while sildenafil acts on PDE5 in the corpus cavernosum (a penile vascular target); there is no pharmacological overlap between these receptor systems and no shared hemodynamic pathway; the combination is safe without any special precautions.
• B) Both tamsulosin and sildenafil produce vasodilation through pharmacodynamically independent but additive mechanisms -- tamsulosin blocks alpha-1 receptors on vascular smooth muscle reducing the norepinephrine-mediated vasoconstriction that maintains blood pressure; sildenafil inhibits PDE5 in vascular smooth muscle, increasing cGMP, which activates PKG to relax smooth muscle and produce vasodilation independently of adrenergic receptor activity; the combined vasodilation from both mechanisms is additive and can produce clinically significant hypotension, particularly orthostatic hypotension, within the first several hours after sildenafil administration; patients must be counseled about this risk and sildenafil should be started at the lowest available dose (25 mg).
• C) Sildenafil competitively inhibits tamsulosin's binding to alpha-1A receptors in the corpus cavernosum by occupying an allosteric site on the alpha-1A receptor that reduces tamsulosin's affinity; this pharmacological antagonism paradoxically reduces the vasodilatory effect of tamsulosin in the penis; the net hemodynamic effect is actually less hypotension than sildenafil alone because tamsulosin's vasoconstriction-reducing effect is blocked by sildenafil at the alpha-1A receptor.
• D) The interaction is pharmacokinetic rather than pharmacodynamic: tamsulosin inhibits CYP3A4, the primary enzyme metabolizing sildenafil; reduced CYP3A4-mediated sildenafil metabolism increases sildenafil plasma concentrations by 3-5 fold; the elevated sildenafil levels produce exaggerated PDE5 inhibition and more profound vasodilation; the clinical management is reducing the sildenafil dose to 12.5 mg to compensate for the pharmacokinetic inhibition by tamsulosin.

12. Yohimbine is a selective alpha-2 adrenergic antagonist. Which of the following correctly identifies the pharmacological consequence of alpha-2 receptor blockade and explains why yohimbine is the pharmacological opposite of clonidine?

• A) Yohimbine is the pharmacological opposite of clonidine because clonidine is an alpha-1 agonist and yohimbine is an alpha-2 antagonist; they act on different receptor subtypes in the same tissue with opposite effects on vascular tone; clonidine activates alpha-1 receptors on vascular smooth muscle producing vasoconstriction and hypertension, while yohimbine blocks alpha-2 receptors on vascular smooth muscle producing vasodilation and hypotension; combining them would produce hemodynamic neutralization.
• B) Yohimbine is pharmacologically inert when given alone; it produces no change in NE release, blood pressure, or sympathetic activity unless clonidine or another alpha-2 agonist is simultaneously administered; when combined with an alpha-2 agonist, yohimbine competitively reverses the agonist effect; it is classified as a neutral antagonist that has no intrinsic activity at the alpha-2 receptor.
• C) Yohimbine produces the pharmacological opposite of clonidine because both drugs act at alpha-2 receptors in the central nervous system; clonidine is an alpha-2 agonist that activates presynaptic alpha-2 receptors in the brainstem reducing sympathetic outflow and lowering blood pressure; yohimbine blocks these same central alpha-2 receptors, removing the inhibitory tone on sympathetic outflow and increasing central NE release, raising blood pressure and heart rate; yohimbine also blocks presynaptic alpha-2 autoreceptors on peripheral sympathetic terminals, disinhibiting peripheral NE release; the net effect is increased sympathetic activity, elevated blood pressure, tachycardia, and CNS arousal -- directly opposite to clonidine's sympatholytic effects.
• D) Yohimbine is the pharmacological opposite of clonidine in the following complete sense: clonidine is an alpha-2 agonist that, by activating presynaptic alpha-2 autoreceptors on sympathetic nerve terminals AND postsynaptic alpha-2 receptors in the brainstem, reduces NE release peripherally and reduces central sympathetic outflow, producing sympatholysis, blood pressure reduction, bradycardia, and sedation; yohimbine, as a selective alpha-2 antagonist, blocks both peripheral presynaptic alpha-2 autoreceptors (disinhibiting NE release from sympathetic terminals and increasing peripheral NE levels) and central postsynaptic alpha-2 receptors in the brainstem (removing the inhibitory tone on central sympathetic outflow and increasing central sympathetic firing); the combined central and peripheral disinhibition of NE produces increased sympathetic outflow, elevated plasma NE, hypertension, tachycardia, anxiety, agitation, and CNS arousal -- a complete pharmacological reversal of clonidine's sympatholytic profile; in patients taking clonidine for hypertension, yohimbine can precipitate acute hypertensive rebound by antagonizing clonidine's mechanism.